This is a phase 3 trial to evaluate the safety and efficacy of YH14755 in subjects with dyslipidemia and Type II Diabetes.~In YH14755 treatment group, 88 subjects will be assigned and the subjects administer YH14755 for 16 weeks.~In Metformin treatment group, 88 subjects will be assigned and the subjects administer Metformin for 16 weeks.~In Rosuvastatin treatment group, 88 subjects will be assigned and the subjects administer Rosuvastatin for 16 weeks.
Randomized, double-blind, active-controlled, multicenter phase 3 trial to evaluate the safety and efficacy of YH14755 in subjects with dyslipidemia and Type II Diabetes.